LC-MS/MS Strategy Using Substructure Searching for the Annotation of Cyanopeptide Classes: Implications for New Compound Discovery and Environmental Monitoring June 20, 2026 | Runjie Xia, Lindsey Ahn, Michaela Burkhauser, Ross Youngs, Matthew J. Bertin* Abstract Cyanobacterial harmful algal blooms (cyanoHABs) are a major ecological and public health concern, commonly monitored for hepatotoxic microcystins and cylindrospermopsins and neurotoxic anatoxins and saxitoxins.
Insilico Medicine And SK Biopharmaceuticals Achieved AI-powered Drug Discovery Collaboration Worth Up to 2.5 Billion for Neuroimmune Disorders (June 22, 2026) by Insilico Medicine CAMBRIDGE, Mass., June 22, 2026 /PRNewswire/ — Insilico Medicine (“Insilico”, 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, and SK Biopharmaceuticals, a Korean-based company leads the way in biotech innovation with groundbreaking drug research,
Merck adds to biopharma’s AI agenda with up to $510M+ Protillion pact (June 17, 2026) by Tristan Manalac Merck will use Protillion Biosciences’ tech to design biologic therapies for therapies across undisclosed indications. The next stop on biopharma’s AI train is Merck, which is bringing on California’s Protillion Biosciences to combine large-scale data generation and AI design to advance a
Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform (June 8, 2026) by J&J Global Media Relations NEW BRUNSWICK, NJ (June 8, 2026) – Johnson & Johnson (NYSE: JNJ) today announced it has entered into a definitive agreement to acquire Firefly Bio, Inc., a biotechnology company advancing its proprietary Firelink™ degrader
PITCH GLOBAL in SAN DIEGO on June 22 June 08, 2026 | By Ross Youngs Ross Youngs, CEO of Biosortia, will be at BIO in San Diego all week and will be presenting at Pitch Global. Let’s discuss how our Grounded Exclusive Biological DATA supercharges Biosortia’s discovery engine. Ask anyone — It’s about the DATA. What can Biosortia’s 13-stage AI
Moderna and other groups get $60 million to develop Ebola vaccine (June 1, 2026) by By Jennifer Rigby, Mariam E Sunny and Julie Steenhuysen Isomorphic Labs, which hasn’t yet disclosed a molecule or reached the clinic, breaks the recent trend of investors putting their money behind more mature and de-risked assets. June 1 (Reuters) – Global health organisation CEPI will
By Biosortia Microbiomics, May 28, 2026 Biosortia: Reversing the Antibiotic Apocalypse—A Global Call to Action WATCH NOW 1. The Existential Threat: Chronic Infections and the Silent Biofilm Catastrophe The world stands on the brink of a medical crisis in which common infections are becoming untreatable. This silent catastrophe is driven by the “Biofilm Barrier”—a sophisticated, multicellular, fortress-like architecture that shields
By Ross Youngs, May 28, 2026 Has synthetic chemical screening hit the wall? Traditional pharma libraries often yield hit rates below 0.1% when searching for complex aging targets. It’s a massive needle-in-a-haystack problem that costs millions and takes years. Even then, once de-risked preclinical, it takes 40 programs to get an approval. Microbiome-based starting point, once de-risked, takes only 4.4
